What is Shoulder Injury Related to Vaccine Administration (SIRVA)?

What is Shoulder Injury Related to Vaccine Administration (SIRVA)?

SIRVA is a rare but potentially debilitating complication that occurs when a vaccine is improperly administered into or near the shoulder's subacromial bursa or synovium rather than the deltoid muscle, triggering an inflammatory cascade that causes persistent shoulder pain, stiffness, and weakness beginning within 48 hours of vaccination. 1, 2

Pathophysiology and Mechanism

The injury results from improper vaccination technique—specifically when the needle is placed "too high" in the arm (reported in 68% of serious cases)—causing the vaccine to be deposited in pericapsular tissue or the subdeltoid bursa rather than the deltoid muscle 1. This misplacement triggers a localized inflammatory response to the vaccine antigen that damages surrounding shoulder structures 2, 3.

Diagnostic Criteria

To diagnose SIRVA, look for this specific constellation:

• Onset within 48 hours of intramuscular deltoid vaccination 1, 2
• Symptoms lasting ≥7 days (distinguishing it from typical post-vaccination soreness) 1
• Pain and decreased range of motion in the vaccinated arm 1
• No pre-existing shoulder symptoms prior to vaccination 4
• 100% of patients report pain, with 90% experiencing multiple symptoms 3

Clinical Presentation

SIRVA predominantly affects:

• Adult females (74% of serious cases) 1
• Rare in children 1
• Average age around 59 years 4

The condition causes significant functional impairment, with 64% of serious cases reporting interference with activities of daily living and/or work absenteeism 1.

Common Pathological Findings

Imaging studies reveal specific patterns of injury:

• Subacromial-subdeltoid bursitis (32-67% of cases) 5, 4, 3
• Adhesive capsulitis (27%) 3
• Rotator cuff tears or tendinopathy (21%) 3
• Polymyalgia rheumatica or PMR-like syndrome (17%) 3
• Less common: biceps tenosynovitis, shoulder synovitis, intramuscular hematoma 5

Diagnostic Workup

When SIRVA is suspected, obtain:

• MRI (most commonly used—56% of cases) for detailed soft tissue evaluation 3
• Ultrasound (28%) for dynamic assessment and bursal evaluation 5, 3
• Radiographs (26%) to exclude bony pathology 3
• Nerve conduction studies are routinely normal 2

Critical Pitfall

In 58% of cases, the initial diagnosis was incorrect, leading to inappropriate treatment 4. Maintain high clinical suspicion when patients present with acute shoulder pain within 48 hours of vaccination, especially when the injection site was noted to be "too high" on the arm.

Incidence and Reporting

The reporting rate is approximately 0.5% of all vaccine adverse events, though this likely underestimates true incidence 1. With mass vaccination programs for COVID-19 and influenza, cases have increased substantially 2.

Prevention

The key to SIRVA is prevention through proper vaccination technique 6. Vaccinators must be trained to:

• Identify the correct deltoid injection site (avoiding the upper third of the deltoid)
• Use appropriate needle length for patient body habitus
• Avoid injecting too high near the acromion

Treatment Approach

Initial management should consist of depot corticosteroids followed by gentle rehabilitation 4. Specifically:

• First-line: Local symptom management with NSAIDs (33% of cases) and physical therapy (35% of cases) 3
• Second-line: Corticosteroid injections for persistent symptoms 4
• Surgical intervention: Reserved for refractory cases despite conservative treatment 4

Prognosis

The majority of SIRVA cases (52%) completely resolve within weeks to months, though the condition can be torpid and difficult to treat 4, 3. Patients who received depot corticosteroids with rehabilitation showed strong clinical improvement, though complete symptom resolution was not universal at 7.2 months average follow-up 4.